Introduction
The tumor suppressor gene p53 is a key regulator of cellular mechanisms that maintain genome integrity (Prives and Hall, 1999) . Normally, cellular stresses such as DNA damage, hypoxia, suboptimal growth conditions, nucleotide pool imbalance and activated oncogenes can induce signaling cascades that converge at p53 and result in greater stability of the protein, primarily through post-translational modi®cations (Giaccia and Kastan, 1998; Meek, 1998; Oren, 1999; Sherr, 1998) . Activated p53 can stimulate transcription of at least 20 target genes through sequence-speci®c DNA binding at promoter elements and through protein-protein interactions (Ko and Prives, 1996; Prives and Hall, 1999) . The DNA binding domain of p53 recognizes a pentameric DNA sequence (consensus 5'-RRRCW-3', R is a purine; W is A or T) (el-Deiry et al., 1992) and a complete p53 binding site consists of two closely spaced head-to-head pentamers (Cho et al., 1994; McLure and Lee, 1998) . The transcriptionally active form of the protein is a tetramer (dimer of dimers). Several p53-activated genes are associated with the induction of programmed cell death (e.g. bax, IGF-BP3, PIG3, Killer/DR5, AIPI) (el-Deiry, 1998; Oda et al., 2000) , regulation of cell cycle through induction of arrest at the G1/S or G2/M checkpoints in response to DNA damage (e.g. p21, GADD45, cyclin G, p53-R2, BTG2, PC3, Reprimo, MCG10, 14-3-3 sigma, PA26), (Cortes et al., 2000; Guardavaccaro et al., 2000; Hermeking et al., 1997; Ohki et al., 2000; Tanaka et al., 2000; Velasco-Miguel et al., 1999; Zhu and Chen, 2000) and modi®cation of p53 stability/activity (MDM2) (Ashcroft and Vousden, 1999) . Among the many REs that are unique for each gene some are poor matches to the p53 binding site consensus. The dierential anity of p53 for the dierent binding sites provides variability in activation of target genes: at a low level, p53 may saturate and activate only high anity elements, while at a high level, p53 saturates and activates binding sites more indiscriminately. In addition, p53 mutants exhibiting subtle defects in DNA binding might retain transcriptional control only of genes containing high anity promoter elements (Ludwig et al., 1996; Resnick-Silverman et al., 1998; Wang and Prives, 1995) .
p53 is mutated in about 50% of all human tumors (Greenblatt et al., 1994) . Nearly 80% of mutations lead to single amino acid changes at highly invariant residues in the DNA binding domain that prevent or reduce DNA binding (Walker et al., 1999) Some p53 mutants can partially inhibit wild type p53 activity when heterozygous (Aurelio et al., 2000; Kern et al., 1992) or lead to gain of functions (Frazier et al., 1998; Lin et al., 1995 ) .
The yeast Saccharomyces cerevisiae provides a useful model system for examining p53 function. p53 can act as a transcription factor for yeast genes containing p53 REs appropriately inserted in their promoters (Scharer and Iggo, 1992) . Functional assays in yeast based on constitutive expression of p53 under the ADHI promoter have provided simple diagnostic tools for characterizing clinical samples (Chappuis et al., 1999; Robert et al., 2000; Flaman et al., 1995) and for evaluating the dominance potential of tumor p53 mutants (Brachmann et al., 1998; Inga et al., 1997a) . Overexpression of p53 in yeast by the inducible GAL1 promoter inhibits growth (Bischo et al., 1992; Nigro et al., 1992) . In separate studies designed to better understand this phenotype, we used the GAL1 promoter to express a panel of human p53 mutations comprising both structural and contact mutants (Rolley et al., 1995; Wong et al., 1999) . Growth inhibition at high expression levels was directly correlated with transactivation activity in that p53 mutants that are defective in transactivation had a relative small growth impact when compared to wild type p53 (see Table 2 and unpublished results).
These observations led us to propose that p53 alleles could be isolated in yeast that would exhibit a stronger eect on growth than wild type p53, possibly leading to inviability. This phenotype might be due to increased DNA binding anity, altered speci®city, longer half-life, increased stability of the tetramer, or stronger protein-protein interactions. Such p53 alleles might function more eectively than wild type p53 and become valuable as research tools in mammalian cells as well and they might help to understand known p53 tumor mutants. Using a recently developed rheostatable GAL1 promoter system that provides graded increases in expression of p53 with increasing amounts of galactose in the medium (Inga et al., 2001) , we have identi®ed and characterized novel p53 alleles that cause lethality in yeast at low expression levels. At even lower expression levels that are compatible with yeast growth these p53 mutants exhibited enhanced transactivation and promoter selectivity that was RE speci®c. One mutant chosen for further analysis was able to re-activate p53 tumor mutations for transactivation of speci®c promoters, retained activity in the presence of dominant negative mutants and suppressed growth when expressed in a human tumor cell line.
Results

Identification of`toxic' p53 mutants
High level expression of wild type p53 in yeast can reduce the rate of cell growth. We sought to identify p53 mutants exhibiting higher levels of growth inhibition compared to the wild type protein anticipating that they would reveal novel features of p53 and enable us to probe its functions. To this end, a pool of random p53 mutants were generated by PCR mutagenesis and screened for their capacity to inhibit growth at high expression level under a GAL1 promoter. Two dierent experimental approaches were used (see Materials and methods).
In the ®rst approach for generating p53 mutants, PCR ampli®cation was carried out on the complete human p53 cDNA, the GAL1 promoter and the TRP1 marker with a couple of primers containing 50 bp tails corresponding to LYS2 sequences that enabled targeted integration into chromosome II via homologous recombination in yIG397 cells. Targeting to a chromosome was preferred initially since p53 overexpression from a plasmid might lead to plasmid loss and aect the analysis of growth inhibition. After puri®cation of the correct integrants (TRP1, lys2), the p53 genes were scored for their ability to transactivate the p53-regulated ADE2 gene (red/white assay) (Flaman et al., 1995) and eect cell growth.
As expected for wild type p53, most of the transformants gave rise to small white colonies when plated on rich medium containing galactose as a high level inducer of the GAL1 promoter plus a small amount of adenine. The white color is determined by wild type p53-dependent ADE2 transcription in the yIG397 strain (Flaman et al., 1995) using the RGC responsive element. About 15% of the isolates were large and red as expected for transactivation-de®cient p53 mutants or if there is no protein produced. One clone among 750 did not grow on medium containing galactose as the only carbon source. In order to verify that the novel phenotype was related to p53, the cDNA fragment comprising nucleotides 124 to 1122 (out of 1182) was ampli®ed using total genomic DNA as template and directly cloned in yIG397 cells by gap repair into a GAL1 expression plasmid (see Materials and methods). Transformants were selected on glucose. When transferred onto galactose medium that select for the plasmid, there was almost no growth, even after 5 days. We concluded that it is possible to identify p53 mutants that can prevent growth with a regulatable promoter system also on a plasmid.
The search for p53 variants with strong inhibition of growth was expanded using a second mutagenesis approach. The p53 cDNA region between nucleotides 124 and 1122 was subjected to random PCR mutagenesis and the DNA was cloned by in vivo gap repair into a centromere-based GAL1 expression plasmid. Among 5000 transformants, we identi®ed 5 isolates that exhibited the no-growth phenotype when highly expressed on galactose plates (see Figure 3 , plates on Toxic p53 mutants A Inga and MA Resnick the right). These isolates are referred to as toxic p53 mutants. The dependence of the phenotype on the p53 region under analysis was con®rmed for all clones by a second round of gap repair involving recovery of the cDNA sequences between nucleotides 124 and 1122. Gap repair of the toxic p53 region was also attempted using an expression vector that utilizes the constitutive moderate ADH1 promoter for p53 expression. Surprisingly, this experiment was not successful: only microcolonies containing less that 50 cells could be detected after 4 ± 5 days of incubation in glucose plates. Similarly it was not possible to isolate colonies if the toxic p53 mutant was ®rst placed next to an ADH1 promoter in vitro and the resulting plasmid transformed into yeast. Thus, we conclude that a p53 toxic mutant can prevent growth even when expressed under a moderate constitutive promoter, where the wild type p53 does not aect yeast growth.
The nature of the mutations in the p53 cDNA of the toxic p53 isolates was determined by DNA sequencing and is presented in Table 1 . The amino acid change(s), their location in the p53 DNA binding domain and the number of identical mutations observed in tumors is also shown. Three identical mutations in isolates 1 ± 3 lead to the same valine to alanine amino acid change at position 122 in the L1 loop of the DNA binding domain. This mutation has not been reported previously. In clone 1 a second mutation (H296R) was detected. A single mutant p53-H296R under control of the GAL1 promoter was constructed and overexpressed in yeast. Its phenotype was not distinguishable from wild type p53 (i.e. moderate growth inhibition and transactivation pro®ciency). The eect of A76T (in clone 3) as a single mutation was not evaluated.
The toxic clone 4 contained two mutations, one at codon 274 and the other at 277. Even though p53 missense tumor mutations have been found in vivo at both codons, the V274I amino acid change appears only three times in the p53 tumor database and C277W is novel. These two mutations have not been separated. Mutant clone 5 also contained two base pair substitutions resulting in amino acid changes at codon 277 in the DNA binding domain (C277R) and codon 338 in the tetramerization domain (F338L). Both changes are novel. Expression of the C277R as a single mutant under the GAL1 promoter on galactose resulted in growth inhibition equal to that of the double mutant. The over-expression of the F338L mutant led to modest growth inhibition and transactivation similar to wild type p53. The mutant clone 6 had the single amino acid change G279R; this mutation has been identi®ed in tumors.
Expression of toxic V122A p53 is lethal and dominant over wild type p53 but not over non-functional p53 mutations
The impact of a toxic mutant on viability as well as growth was examined with p53-V122A. Cells containing an integrated copy of wild type p53 or toxic V122A were grown in liquid media containing galactose and plated to glucose plates at various times to repress p53 expression. Wild type p53 inhibited growth modestly compared to the control strain and had a high plating eciency (Figure 1 ). In contrast, V122A inhibited growth completely (no increase in cell titer) and reduced the absolute number of viable cells. After 24 h of incubation in galactose medium, only 7% of the cells gave rise to colonies on glucose plates. p53 protein expression under the GAL1 promoter was also evaluated. A nonfunctional truncated mutant (Q331 Stop) that does not aect growth was included for comparison ( Figure 2 ). Cells were induced in galactose for 2 h (lanes 1 ± 3) or 4 h (lanes 5 ± 7) and protein extracts examined by Western blot. The expression level of V122A was similar to wild type p53. Thus, we conclude that the toxicity of V122A is not due higher Figure 1 Lethality of V122A p53 mutant. Isogenic yeast cells containing an integrated wild-type p53 or V122A GAL1 expression construct were grown overnight in glucose medium, washed and diluted to 10 6 cells/ml and grown in galactose medium. Aliquots were taken at the indicated times, titers were determined, and cells were plated on glucose medium to assess viability. Mean and standard errors for a triplicate set of experiments are presented. Squares correspond to cell number; triangles correspond to viable cells 
Growth is prevented by expression of the mutant p53 from a GAL1 inducible promoter under conditions of galactose-induced high level expression or the lower level ADH1 constitutive expression (see text). b Based on the crystal structure of the DNA binding domain (Cho et al., 1994) .`Outside' indicates external to the DNA binding domain. c Based on the April 1999 release of the p53 tumor database containing 11110 entries (Hernandez-Bouissard et al., 1999) . identical'=number of tumor mutants in the p53 database that have the same amino acid substitution identi®ed in the yeast assay Oncogene Toxic p53 mutants A Inga and MA Resnick levels of p53 but rather to some other features of this mutation. The V122 residue is located in the L1 loop of the DNA binding domain that is involved in sequencespeci®c DNA binding (Cho et al., 1994) . A possible explanation for the toxicity is that the V122A change aects DNA binding speci®city/anity in a way that somehow leads to general toxicity in yeast. If this were true, co-expression of V122A with p53 tumor mutants that are defective in DNA binding might be expected to interfere with the toxic eect, provided that heterotetramers are formed. To explore this possibility, the V122A mutant and wild type or tumor p53 mutants were co-expressed at equal levels with the GAL1 or the ADH1 promoters on selectable plasmids constructed in vitro and co-transformed in yeast ( Table  2 ). The tumor p53 mutants were defective for transactivation and some were dominant negative (Inga et al., 1997a) . Wild type or truncated p53 could not relieve V122A toxicity. The various p53 missense mutations reduced toxicity of V122A only slightly when the proteins were highly expressed under the GAL1 promoter. However, toxicity was relieved with ADH1 driven moderate expression. These results suggest that the toxic eect of V122A is mediated through DNA binding.
Transactivation capability of toxic p53 mutants with various responsive elements
In order to evaluate the transactivation potential of the toxic p53 mutants we examined the consequences of low level expression of p53 using a recently developed rheostatable GAL1 promoter system that provides increasing expression of p53 with increasing amounts of galactose in the medium (Inga et al., 2001) . The GAL1 promoter is repressed in glucose, and derepressed (but not induced) on ranose. Addition of small amounts of galactose to ranose plates leads to variable induction of GAL1 transcription. Thus, the transactivation capability of the mutant p53s can be assessed at expression levels that are not toxic. None of the toxic mutants could activate transcription of ADE2 from a minimal yeast promoter containing three copies of the RGC responsive element (Figure 3a) . At 0.003% galactose (center) transformants with wild type p53 were white, while those with toxic p53 exhibited good growth but remained red. At 0.3% galactose only wild type p53 allowed growth (2% galactose was used in the initial screen for toxic mutants). This result contrasts with the observation of a direct relation between growth inhibition and the DNA binding/transactivation ability of various p53 mutants (unpublished results and Table 2) .
We explored the possibility that toxic alleles might possess altered sequence recognition. For example, they might exhibit a defect in transactivation for some promoter elements but show wild type or even enhanced activity for others. Surprisingly, when tested with a p21 RE reporter system (p21RE::ADE2) all toxic p53 alleles, except p53-G279R, activated transcription when cells were transferred to plates containing only ranose (Figure 3b ). Since there was no transactivation by wild type p53 at the same low basal protein expression level, the mutants clearly were greatly enhanced for transactivation with a p21 responsive element. This super-transactivation capability was similar to that of the recently described supertrans mutants (Inga et al., 2001) . (As expected, the white colonies did not require adenine for growth) (data not shown). G279R also could transactivate with the p21 responsive element, but only at a higher protein expression (ranose + 0.003% galactose), Figure 2 Expression of V122A toxic p53. yIG397 cells expressing wild type p53 (wt), the V122A toxic mutant or the truncation mutant Q331Stop under control of a GAL1 promoter from an integrated construct were incubated in galactose medium or ranose medium as control (only wt; lane 4) and extracts were prepared after 2 or 4 h. Twenty mg of protein extract were loaded per lane. p53 was detected using antibodies pAb1801 and DO-1 (Santa Cruz) p53 expression plasmids were constructed in vitro and cotransformed into yeast. The same promoter (GAL1 or ADH1) was used to achieve equal expression of both alleles. For the GAL1 promoter, growth was monitored on galactose plates; for the constitutive ADH1 promoter, growth was scored on glucose plates.
b Dominant negative mutation for transactivation when heterozygous with wild type p53 (Inga et al., 1997a) Toxic p53 mutantssimilar to wild type p53. Unlike for p21, none of the mutants exhibited activation of ADE2 under conditions of basal expression (on ranose only) when the bax responsive element was tested (Figure 3c ). However, in the presence of 0.003% galactose (center) the V122A mutant gave rise to light pink colonies. This indicated enhanced activity since wild type p53 as well as the other mutants yielded only red colonies. At higher level of expression wild type p53 yielded white colonies, while all toxic mutants prevented growth. Thus, the defects associated with the toxic mutants are not related to an inactivation of transactivation capability. The system for low level expression of p53 can reveal strong transactivation capabilities as well as dierences in transactivation capabilities between the various toxic mutants and the dierent p53 responsive elements (RGC, p21 and bax). It also appears that the dierence in relative DNA binding anity of wild type p53 for the bax and p21 responsive elements observed in vitro (Wieczorek et al., 1996) and with human cells (Ludwig et al., 1996; Thornborrow and Manfredi, 1999) can be functionally characterized in yeast under conditions of low protein expression.
V122A can reactivate p53 tumor mutants for transactivation with the p21 and bax responsive elements Based on the supertrans ability, a toxic mutation in cis might be able to reactivate a nonfunctional tumor mutation. We examined this with the V122A mutation because of its location in the L1 loop (a cold spot for tumor mutations; Hernandez-Boussard et al., 1999) and because it was the only toxic mutant to be supertrans for both the p21 and bax REs. Several double mutants formed between V122A and tumor p53 mutations were expressed under the GAL1 promoter at high level of expression in the yIG397, yPH-p21 and yPH-bax reporter strains and eects on growth and transactivation were assessed (Table 3) . As expected the p53 double mutant V122A::Q331Stop did not inhibit growth. Several double mutants with missense tumor mutations were no longer toxic but exhibited a moderate growth inhibition similar to wild type p53. As expected none of the double mutants exhibited transactivation with the RGC RE. Only the double mutants V122A::L252F and V122A::R282Q could transactivate the bax::ADE2 reporter. On the contrary, several double mutants produced white or pink colonies in yPH-p21, indicating that the transactivation function had been partially or completely restored. Surprisingly, the truncated p53-V122A::Q331Stop also produced pink colonies. The relative binding anity of p53 for the p21 and bax responsive elements may explain the dierent abilities to reactivate mutations. These results using double mutants in cis, along with the observation that V122A retains a wild type like growth inhibition when co-overexpressed with p53 a b c Figure 3 Evaluation of the transactivation capabilities of toxic p53 mutants. Transactivation was assessed on plates containing low adenine and ranose as carbon source. Small amounts of galactose were added to achieve variable GAL1 induction. The RGC, p21 and bax responsive elements were tested in panels a, b and c respectively. White/pink colonies are indicative of p53 dependent transactivation. Lack of p53 transactivation results in colonies becoming red (the dark colonies in this ®gure). Mutants correspond to those in Table 1   Table 3 Impact of a cis V122A toxic mutation on various tumor p53 mutants when the double mutant is over-expressed under the GAL1 promoter in yIG397, yPH-p21 and yPH-bax reporter strains 
Expression of V122A in human cells
The V122A mutation has not been reported in tumors nor studied in mammalian cells or in vitro. Our results in yeast suggest V122A might be useful for functional studies of p53-regulated downstream pathways because of its altered promoter recognition and enhanced transactivation. In order to examine its biological activity in human cells, the consequences of expression were examined in the p53-null Saos-2 cell line. As shown in Figure 4 , p53-V122A was similar to wild type p53 in its ability to suppress colony formation (10% relative colony formation). The presence of a truncation mutation, V122A::Q331Stop, prevented the suppression of growth, suggesting that tetramerization is required. It is interesting that the relatively small eect on colony formation by the G279E mutant was increased when a second V122A mutation was included (65% vs 30% relative colony formation for G279E and V122A::G279E, respectively). The ability to induce the chromosomal p21 gene during transient transfection was also examined ( Figure 5 ). The V122A protein was as eective as wild type for the induction p21). As expected, G279E induced p21 very poorly; however, the double mutant V122A::G279E was partially active. The level of V122A p53 protein was comparable to wild type p53, while G2799E and V122A::G279E levels were higher. These results are similar to the yeast transactivation analysis, in that there was induction of p21 by V122A and there was some reactivation of the G279E mutation, although not to a wild type level. The double mutant V122A::G279E suppressed Saos-2 growth signi®cantly, as noted above. The low induction of p21 by V122A::G279E may be responsible for this growth suppression, but we cannot exclude the involvement of other p53-mediated responses independent from the p21 function.
The transactivation potential of V122A was also tested using plasmid-based luciferase reporter assays. V122A exhibited a wild type level of activity when tested with the p21 promoter and the double mutant p53-V122A::G279E was not re-activated (Figure 6a) . Interestingly, V122A induced luciferase at a higher level compared to wild type p53 with the bax responsive element (Figure 6b ). This eect was not due to a dierence in p53 expression ( Figure 5 ).
Discussion
Yeast has proven to be a useful system for the functional evaluation of p53 alleles. The use of reporter systems in yeast that utilize promoter elements from human genes recognized by p53 has found many applications as a diagnostic as well as a research tool (Brachmann et al., 1996; 1998; Chappuis et al., 1999; Flaman et al., 1995; 1998; Freeman et al., 1994; Inga et al., 1997b; Ishioka et al., 1995) . In previous works p53 expression was achieved using the constitutive moderate ADH1 promoter. Although it was shown that overexpression of human p53 under the GAL1 promoter could lead to inhibition of yeast growth (Nigro et al., 1992) , no such eect has been reported for ADH1 driven p53 expression. We hypothesized that Figure 4 Growth suppression by p53 in Saos-2 cells. Saos-2 cells were transfected by lipofectin in T25¯asks using 1.5 mg of pCMV-Neo-Bam plasmid DNA containing dierent p53 alleles under the control of a CMV promoter. The relative mean number and the standard deviations for at least three independent experiments are presented Figure 5 Induction of p21 in Saos-2 cells. Saos-2 cells were transiently transfected by pCMV-based plasmids (100 ng) with wild type or mutant p53 using lipofectin. Cells were recovered after 48 h. The amount of protein extract loaded in each lane is indicated. After transfer, the membrane was cut at a position corresponding to a 40 kD marker in order to detect p21 (with antibody pAbC19) and p53 (with antibodies pAb1801 and DO-1) separately. To detect alpha-tubulin, the membrane was stripped and reprobed Toxic p53 mutantsgrowth inhibition by p53 could be directly related to its ability to interact with the DNA and that p53 alleles with a stronger impact on growth might be identi®ed. In this work four (or possibly ®ve) amino acid changes causing p53 to be toxic have been recovered after random mutagenesis of the p53 DNA binding and tetramerization domains. Our results indicate that the isolation of toxic p53 mutants in yeast is only possible using conditions of low expression and/or regulatable expression but not with constitutive ADH1 expression. The GAL1 promoter would be ideal for such a study, since its level of induction can be modulated by varying the nature and the amount of the sugar(s) in the medium, as we showed in a recent work (Inga et al., 2001) .
Among six independent toxic p53 isolates, the novel amino acid change V122A was recovered three times, suggesting that the screen may be representative of available mutations. Position V122 is invariant among p53 protein sequences from 20 dierent species (Soussi and May, 1996) and it belongs to the L1 loop (Cho et al., 1994) which is part of the loop-sheet-helix motif that provides major groove contacts to the DNA. Despite the high evolutionary conservation and the role in establishing DNA contacts, the L1 loop is surprisingly a cold-spot region for tumor mutations (Hernandez-Boussard et al., 1999) . We recently used a random mutagenesis protocol and a functional selection in yeast to isolate p53 allelic variants exhibiting super transactivation at low expression level for the RGC responsive element (Inga et al., 2001) . Interestingly, several mutations aected amino acids in the L1 loop including S121, T123, and C124. Similar to the present study, those mutations also led to a no-growth phenotype upon over-expression; however they did not inhibit growth when expressed under an ADH1 promoter. The V122A mutant was de®cient for transactivation with the RGC responsive element but showed enhanced activity with both p21 and bax elements (Figure 3 ) and prevented growth when expressed under the ADH1 promoter. Thus, mutations at adjacent residues in the L1 loop confer altered sequence recognition with dierent speci®cities and exhibit dierent levels of impact on yeast growth.
A p53 variant with enhanced transactivation may be able to restore activity to non-functional mutations elsewhere in the DNA binding domain, thus acting as an intragenic suppressor. The extent of re-activation is also likely to be aected by the relative anity of p53 for a given responsive element and the degree of perturbation introduced by the non-functional mutation. These features were explored with V122A by constructing a panel of double mutants and testing transactivation with dierent p53 responsive elements. Interestingly, this mutation when combined with several tumor p53 mutations regained some transactivation activity with the high anity p21 responsive element, but only a few double mutants were active with the lower anity bax RE (Table 3) . Enhanced transactivation may be also expected to overcome dominant negative eects of DNA binding mutations in heterotetramers (Inga et al., 2001) .The phenotypic impact of co-expressed V122A together with common tumor mutations (Table 2 ) is in agreement with this prediction. These features suggest that p53 alleles such as V122A might be valuable both for functional studies of p53-regulated cellular responses and possibly for p53-based cancer gene therapy. Many tumors express at high levels p53 mutant proteins that can act in a dominant negative fashion. This might limit the success of gene therapy approaches based on wild type p53 gene delivery (Clayman et al., 1998; Gallagher and Brown, 1999; Saller et al., 1999; Swisher et al., 1999; Vinyals et al., 1999; Wolf et al., 1999) . Alleles with enhanced activity, especially in activating apoptosis inducing genes, might achieve a higher therapeutic index.
Mutations at codon 277 and 279 also caused toxicity in yeast. We cannot exclude the possibility that the V274I change also contributes to the toxic phenotype as the two mutations in isolate number 4 (Table 1) were not studied separately. The amino acids C277 and G279 are invariant among p53 protein sequences. Interestingly, cysteine 277 directly contacts the DNA sequence in the major groove at the third base of the pentameric consensus (Cho et al., 1994) . Mutations at this codon have been detected in tumors, but neither C277R nor C277W are tumor mutants. Both in vitro and functional studies showed that amino acid changes at position 277 can lead to changes in DNA binding (Chene, 1999; Saller et al., 1999; Thukral et al., 1995) . For instance, the tumor mutant C277Y revealed altered DNA binding speci®city in yeast and human cells and was defective for transactivation of common REs (Gagnebin et al., 1998) . Our transactivation analysis at low expression level with both V2741::C277R and C277W showed DNA binding speci®city and enhanced activity for the p21 RE. This latter feature may explain why these mutations are not selected in tumors.
Our study has revealed that the G279R tumor mutation also has a toxic phenotype when expressed in our yeast system. Other mutations have been identi®ed at G279 that impair p53 transactivation function including the G279E mutant used in the present study (Hernandez-Boussard et al., 1999) . Unlike G279R the over-expressed G279E had no or very little growth inhibitory eect and was completely defective in transactivation assays. We did not observe transactivation with RGC or bax by G279R, but transactivation was normal with the p21 RE. One possibility is that G279R toxicity in yeast results from altered sequence recognition and even enhanced activity for others responsive elements we did not test. In mammalian cells its novel promoter selectivity may result in a gain and/or loss of functions that are compatible with tumor progression.
Interestingly, all the toxic mutants identi®ed in our study aected amino acids that occupy the same region of the p53 DNA binding domain. The L1 loop and H2 helix interact in the tertiary structure to form the loopsheet-helix motif that established DNA contacts (Cho et al., 1994) . This suggests a common mechanism for the toxic phenotype that might be related to perturbations of DNA interactions. For instance, several close matches to the p21 responsive element were identi®ed in the yeast genome (Tom Darden, unpublished results). Binding of p53 proteins at such sites might aect transcription or other DNA transactions. However, the reason for the toxic phenotype awaits further investigations.
Previously the p53 functional assay in yeast was repeatedly shown to be reliable and sensitive at characterizing typical p53 inactivating mutations isolated from human tumors. However, the ability to predict responses in human cells of p53 mutants with altered function needs to be evaluated. In Saos-2 cells (p53 null), expression of V122A suppressed growth to the same extent as wild type p53. It is interesting that, similar to results in yeast, the double mutant V122A::G279E resulted in decreased colony formation compared to the single mutant G279E. V122A did not show higher induction of the p21 promoter compared to wild type p53 and did not completely re-activate G279E. The p21 promoter contains two dierent p53 responsive elements with dierent anities for p53 (Thornborrow and Manfredi, 1999) . The relative contribution of each responsive element to p21 expression is not well characterized. In the yeast reporter system only the 5' p21 responsive element has been studied. Thus, it is possible that V122A possesses a decreased anity for the 3' p21 responsive element and the overall promoter induction is similar or even reduced compared to that achieved by wild type p53. The V122A mutant showed about four times higher luciferase activity than wild type p53 with the bax responsive element. In this case the same p53 binding sequence is used in the mammalian and yeast reporter and the transactivation results are similar. The toxic mutations at residues 277 and 279 also suppressed growth like wild type p53 in Saos-2 cells (data not shown). The transactivation capabilities of these mutants have not been studied.
Our experiments in human cells suggest that the selection for toxic p53 alleles in yeast may be useful in identifying p53 variants with relevant biological functions. The combination of toxic phenotype as a screening tool and transactivation analysis at low expression levels provides a very sensitive experimental approach for identifying and characterizing p53 mutants with altered DNA binding speci®city. Such mutants could be useful in the functional dissection of downstream p53 regulated pathways and in the identi®cation of novel p53 transcriptional targets by gene expression pro®ling. Moreover, our yeast assays would allow broader detection and more precise functional characterization of a variety of subtle p53 mutants that may originate during tumorigenesis and would not be revealed with standard functional assays based on constitutive p53 expression.
Toxicity in yeast could also be exploited in order to screen for small molecules or peptides that can modify functions of a wild type or a mutant p53 protein and turn it into a toxin. This analysis could provide leads for drug modi®cation of p53's in tumors, expanding similar in vitro and cell culture screens (Foster et al., 1999; Selivanova et al., 1999) . Alternatively, chemicals or peptides could be screened for the ability to inhibit p53 toxicity in yeast. These molecules might be employed for temporary inactivation of p53 function in vivo as proposed in a recent study (Komarov et al., 1999) .
Materials and methods
Yeast strains, plasmids, media and reagents
The haploid S. cerevisiae strain yIG397 (Mata ade2-1 leu2-3,112 trpl-1 his3-11,15 can1-100 ura3-1, URA3 3xRGC::CY-C1::ADE2) was originally constructed to assess p53 transactivation by Richard Iggo (Flaman et al., 1995) and was kindly provided together with yeast p53 expression plasmids. The strain contains an integrated copy of ADE2 under control of a minimal CYC1 promoter. Three copies of the human p53 responsive DNA element found at the ribosomal gene cluster (RGC: 5'-GGACTTGCCTGGCCTTGCCT-3') are inserted in the upstream region of the promoter. Thus, ADE2 is under p53 transcriptional control and transactivation by p53 alleles can be easily scored based on the color or yeast transformants on suitable plates. Colonies expressing wild type p53 grow like adenine prototrophs yielding white colonies on plates containing a limiting amount of adenine Toxic p53 mutantswhile small red colonies appear when a nonfunctional p53 is expressed. The haploid strains, YPH-p21 (MATa ura3-52 lys2-801 ade2-101 trp1-D63 his3-D200 leu2-D1 URA3 p21::pCYC1::ADE2) (p21 p53 binding site is a 20 mer sequence found 2.4 kb upstream of the p21 promoter, and YPH-bax (MATa ura3-52 lys2-801 ade2-101 trpl1-D63 his3-D200 leu2-D1 URA3 bax::pCYC1::ADE2) (bax p53 binding site is a 39 mer sequence found 486 ± 448 bp upstream of the bax promoter) were kindly provided by Dr Thierry Frebourg. They allow the evaluation of p53 transactivation function as in yIG397, but the p53 responsive element controlling ADE2 transcription has been changed into the p21 and bax promoter elements, respectively (Flaman et al., 1998) .
Plasmid pLS76 encodes the complete human p53 cDNA under the control of the constitutive ADH1 promoter. The plasmid is based on pRS315 (LEU2). pLS89 is a yeast expression vector coding for the p53 cDNA under control of the strong inducible GAL1 promoter. Plasmid pRDI-22 is identical to pLS76 except for the BsmI::StuI deletion at p53 replaced by a HindIII::StuI linker. Plasmid pLS89 (after BsmI::StuI digestion and gel puri®cation) and pRDI-22 (HindIII::StuI digested) were used for gap repair cloning, as previously described (Flaman et al., 1995) . Brie¯y, PCR ampli®cations of a p53 cDNA fragment between positions 124 and 1122 were co-transformed in yIG397 together with the linear gapped plasmid. Since both ends of the PCR product overlap with the linear plasmid (75 and 80 bp, respectively at the 5' and the 3'-ends), homologous recombination can occur in vivo to reconstitute the complete p53 cDNA and a circular expression vector.
Plasmids pCMV-Neo-Bam and pC53-SN3 (Baker et al., 1990) coding for the human p53 cDNA under control of the CMV promoter were provided by Dr Bert Vogelstein and were used for expression studies in mammalian cells. Speci®c mutant p53 plasmids were constructed by replacing the SgraI ± StuI p53 portion with the same fragment of pLS89 derivatives. Plasmids pGL1012 and pGL1138 contain respectively the bax and p21 promoters regulating the luciferase gene. They were kindly provided by Dr. Moshe Oren.
Yeast strains were cultured in 1% yeast extract, 2% peptone, 2% dextrose (YPD) or with the addition of 200 mg/ L adenine (YPDA) or on selective medium when appropriate. p53 transactivation was generally determined in synthetic medium containing 5 mg/l adenine. Growth inhibition was analysed on plates containing 2% galactose as carbon source. To determine the transcriptional potential of the p53 toxic allele, plates containing 2% ranose (Sigma, St. Lous, MO, USA) as carbon source and a variable low amount of galactose were used. In the presence of ranose the GAL1 promoter is derepressed and can be induced by addition of galactose to the medium.
Random mutagenesis, PCR integration in yeast, DNA recovery and analysis
Plasmid pLS89 was used as a template for PCR using the TAQ Long Plus polymerase mix (Stratagene, La Jolla, CA, USA) under optimal reaction conditions. A pair of universal primers for pRS vectors (designed by Dr Kevin Lewis) was used to generate a 5 kb fragment that includes the sequence for the p53 cDNA, its GAL1 promoter and the yeast selection marker TRP1. The primers also have 50 bp tails corresponding to segments of the LYS2 gene to allow speci®c chromosomal integration of the fragment. PCR products were puri®ed by precipitation and used to transform yIG397 competent cells by the LiAc protocol (Flaman et al., 1995) . Transformants were selected on synthetic medium lacking tryptophan and tested for lysine auxotrophy. Puri®ed TRP1-lys2 clones were then tested on galactose plates with low adenine to assess p53 dependent growth inhibition and transactivation. A total of 750 integrants were analysed. The frequency of polymerase errors leading to functional p53 mutations in the PCR reaction was estimated in a separate assay as follows: ampli®cation of the p53 cDNA was carried out between nucleotide 124 and 1122, gap repair was performed with pRDI-22. The percentage of red colonies among the transformants was determined. In the chosen PCR ampli®cation conditions, 15% of transformants gave rise to red colonies.
To recover the p53 fragments from yeast clones with integrated p53, genomic DNA was prepared by standard methods and the p53 fragment between nucleotides 124 and 1122 (out of 1182 of the total cDNA) was ampli®ed by PCR with primers P3 and P4 (Flaman et al., 1995) In order to con®rm that the phenotype observed in the original clone was due to the p53 region containing the DNA binding domain, PCR products were cloned using gap repair in pLS89. These products were then sequenced using an AB1377 automated sequencer (Applied Biosystems, CA, USA).
Since toxic p53 mutants could also be seen when they are expressed from a centromeric plasmid in yIG397 cells, a random PCR mutagenesis screen was also performed on the p53 cDNA fragment between nucleotides 124 and 1122. Dierent mutagenic conditions for the ampli®cation were used (Lin-Goerke et al., 1997) . Gap repair was carried out using the pLS89 vector and transformants were obtained on glucose plates selective for the plasmid marker. Yeast transformants were screened by replica plating onto galactose plates and clones were identi®ed that did not grow when p53 was expressed. The plasmid was recovered from these clones and the p53 cDNA was ampli®ed by PCR and re-cloned by gap repair into pLS89 to con®rm the phenotype, and then sequenced.
Western blots yIG397 derivatives with integrated p53, or transformants with p53 expression plasmids, were cultured overnight in glucose medium selective for the plasmid. Cells were washed and diluted in galactose-containing medium to induce the GAL1 promoter. Aliquots were collected at various times. Protein extracts were prepared in lysis buer (100 mM NaPhosphate pH 7.0; 1 mM EDTA; 0.1% SDS; 16protease inhibitor cocktail, Roche, Idianapolis, IN, USA) with the aid of sterile acid-washed glass beads (0.45 ± 0.6 mm). Protein concentration was measured by the Bradford assay (Biorad, Hercules, CA, USA) according to the standard protocol. Precast SDS ± PAGE gels (PAGE ± ONE, Owl Separation Systems) were used for electrophoresis. Proteins were transferred to PVDF membrane (Immobilon-P, Millipore, Bedford, MA, USA) using a semi-dry electroblotter (Owl Separation Systems, Portsmouth, NH, USA) according to instructions. p53 was detected using both pAb1801 and DO-1 monoclonal antibodies (Santa Cruz, Santa Crux, CA, USA) according to protocol.
Transfections in Saos-2 cells, luciferase assays and Western blots
The human osteosarcoma derived p53 null cell line Saos-2 was used for p53 expression experiments. Cells were cultured in McCoy's 5A medium with 15% FBS serum (Life Technologies, Grand Island, NY, USA). T25 cm 2 cell cultures asks were seeded and transfected at 60% con¯uence by lipofectin reagent (Life Technologies). For stable transfections, 1.5 mg of puri®ed plasmid DNA was used. Cells were selected by adding G418 (Life Technologies) at 0.5 mg/ml after 1 day of recovery in complete medium following removal of lipofectin. Colonies were stained with Coomassie Blue after 2-3 weeks; approximately 4000 colonies were scored in transfections involving the vector control.
p53 transactivation assays were done using 50 ± 100 ng of p53 expression plasmid and 1 mg of luciferase vectors in transient transfections. Cells were recovered after 24 h. Protein concentration was measured by the Bradford assay (Biorad, Hercules, CA, USA). Luciferase activity was measured by the Luciferase Assay System (Promega, Madison WI. USA) and using the single photon monitor program in a scintillation counter (Beckmann, Irvine, CA, USA). For Western blot p21 was detected using C-19 polyclonal antibody (Santa Cruz Biotech, Santa Cruz, CA, USA). a-tubulin was used as an internal loading and transfer control and detected by a monoclonal antibody (B-5-1-2, Sigma, St. Louis, MO, USA).
